#POLB Poolbeg Pharma PLC – Metabolic diseases oral delivery licence signed

Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, […]

#TEK Tekcapital PLC – Change in Accounting Reference Date

Tekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating valuable products from investing in university technology that can improve people’s lives, announces that it is changing its accounting reference date from 30 November to 31 December. As a result of the change of accounting reference date, the Company’s reporting calendar will […]

Kavango Resources PLC #KAV – Holding(s) in Company

TR-1: Standard form for notification of major holdings   1. Issuer Details ISIN GB00BF0VMV24 Issuer Name KAVANGO RESOURCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Purebond Limited City of registered office (if applicable) Wembley Country […]

#TYM Tertiary Minerals plc -Update -Copper Projects, Zambia

Tertiary Minerals plc is pleased to announce that it’s local partner and licence holder Mwashia Resources Ltd (“Mwashia”) has now received approval of Environmental Project Briefs (“EPBs”) from the Zambian Environmental Management Agency (“ZEMA”) for the Konkola West and Lubuila Copper Projects where the Company is earning up to a 90% interest. The Company is […]

Power Metals Resources #POW – Kalahari Key Acquisition Complete – Power Metal Now Holds 87.71% Interest. Molopo Farms Drilling Update

Power Metal Resources PLC (LON:POW),  the London listed exploration company seeking large-scale metal discoveries across its global project portfolio announces the completion of the transaction to increase the Company’s interest in Kalahari Key Mineral Exploration Pty Limited (“KKME” or “Kalahari Key”) further details of which were provided in the Company’s announcement of 3 November 2022 […]

#KAV Kavango Resources Plc – Publication of Prospectus

Further to the announcement of 24 October 2022 in which Kavango announced it had conditionally raised £3,000,000 before expenses by the issue of 166,666,660 new ordinary shares of £0.001 each in the capital of the Company (the “New Ordinary Shares”) at a price per share of 1.8 pence, the Company is pleased to announce that […]

#SVML Sovereign Metals Limited- Result of AGM

The Annual General Meeting (AGM) of Sovereign Metals Limited (Company) (ASX:SVM, AIM:SVML) was held today, 18 November 2022, at 10.00am (AWST). The resolutions voted on were in accordance with the Notice of AGM previously advised to the Australian Securities Exchange and shareholders. All resolutions were decided on and carried by way of poll. In accordance […]

#HVO hVIVO plc – Investors’ Chronicle

Building on decades of experience, hVIVO is currently the only CRO focused on challenge studies, providing world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary. hVIVO contract awards Since the release of interim results in early September, hVIVO has announced a massive £13.4mn contract with a US biotechnology client, a repeat customer, to test its respiratory syncytial virus antiviral candidate using hVIVO’s established RSV Human Challenge Study Model. Although difficult to assess the challenge study market, Liberum Capital estimates there are around 20 challenge studies conducted each year. Using the prevailing average contract size of £6.7mn, this indicates £100mn-£135mn of challenge study work each year, excluding any additional income through manufacturing and validating bespoke challenge agent. Around 60 per cent of hVIVO’s current order book relates to biotech customers and the balance relates to big pharma, with the group carrying out three active challenge studies for big pharma in the first half of 2022 and two full-service challenge studies with values exceeding £25mn. Moreover, hVIVO has signed up eight challenge studies with big pharma companies since 2018, 12  and all the big pharma clients are repeat customers. Improving financials Backed by a bumper order book and having booked £9mn of group revenue in July and August 2022, house broker FinnCap expects the group’s hVIVO division, which carries out the challenge studies, to grow revenue from £29.4mn last year to £42.5mn in 2022 and account for 82 per cent of its total revenue estimate of £51.1mn. Furthermore, taking account of challenge study contract wins, revenue from Venn Life, laboratory services and non-challenge studies, the brokerage estimates that £53mn of its 2023 revenue estimate of £56mn is already covered. SGS’s expertise is in performing influenza challenge studies, but it also has Malaria challenge, and RSV challenge models.

#POLB Poolbeg Pharma Plc- Capital Markets Day

17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm.   The event, which […]